A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

Exclusion Criteria

• •1. History of
• •* Lymphoproliferative disorder
• •* Active malignancy;
• •* History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix).
• •2. High risk of thrombosis or cardiovascular disease
• •3. High risk of herpes zoster
• •4. Active or recent infection